Skip to main content
Fig. 4 | Clinical Proteomics

Fig. 4

From: Targeting LAMP2 in human cerebrospinal fluid with a combination of immunopurification and high resolution parallel reaction monitoring mass spectrometry

Fig. 4

Scatterplots comparing LAMP2 peptide levels between AD and control subjects. Employing the IP-HR-PRM-MS method the level of three LAMP2 peptides were compared between a set of control (n = 14) and Alzheimer’s disease (AD; n = 14) subjects. a Significant higher level of the peptides a LAMP2 aa 133–144 (p = 0.024, 95 % CI 0.043–0.81) and b aa 145–152 (p = 0.039, 95 % CI 0.015–0.75) was found in the AD compared to the control group. This was not significant for the c aa 153–161 peptide (p = 0.10, 95 % CI −0.094 to 1.12). Shown is the calculated ratio between the sum of the included fragment ion peak areas of the tryptic peptide against the sum of peak areas of the added isotope labeled peptide for each individual subject. For each group the median and interquartile range are indicated. Groups were compared using Mann–Whitney’s U test of ranks

Back to article page